C3 Glomerulopathy Clinical Trials

26 clinical trials for C3 Glomerulopathy across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN — RECRUITING · PHASE3
• Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study — RECRUITING · PHASE4
• A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy — RECRUITING · PHASE1
• A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy — RECRUITING
• Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN — RECRUITING · PHASE2
• Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy — RECRUITING · PHASE2
• Home Reported Outcomes in C3G Study — RECRUITING
• National Registry of Rare Kidney Diseases — RECRUITING
• A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients with C3-Glomerulopathy — TERMINATED · PHASE1
• Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) — NOT_YET_RECRUITING · PHASE2
• Fabhalta Capsules Specified Drug-use Survey — ACTIVE_NOT_RECRUITING
• Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease — COMPLETED · PHASE1
• Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN — COMPLETED · PHASE2
• Study of NM8074 in Adult C3 Glomerulopathy Patients — NOT_YET_RECRUITING · PHASE1
• An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis — ACTIVE_NOT_RECRUITING · PHASE3
• Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis — COMPLETED · PHASE3
• CHART-C3G/CLNP023B12011 — NOT_YET_RECRUITING
• Managed Access Programs for LNP023, Iptacopan — OTHER
• C3G/Primary IC-MPGN EAP — OTHER
• Controlled Trial Evaluating Avacopan in C3 Glomerulopathy — COMPLETED · PHASE2
• A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases — NOT_YET_RECRUITING · PHASE2
• Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting enzyme inhibitor, enalapril, in children and adults with C3 glomerulopathy — OTHER · PHASE2
• A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 — TERMINATED · PHASE2
• A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) — COMPLETED · PHASE2
• Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study — COMPLETED · NA
• A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN — COMPLETED · PHASE2

Refine this search